| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EURURO.2012.08.053 |
| P8608 | Fatcat ID | release_6gzokj6bxve5db3fru2fub3uly |
| P932 | PMC publication ID | 3615043 |
| P698 | PubMed publication ID | 22981675 |
| P5875 | ResearchGate publication ID | 230862166 |
| P50 | author | Garrett M Frampton | Q30502367 |
| Mark Rubin | Q37375521 | ||
| P2093 | author name string | David M Nanus | |
| Philip J Stephens | |||
| Himisha Beltran | |||
| Scott T Tagawa | |||
| Doron Lipson | |||
| Juan Miguel Mosquera | |||
| Theresa Y MacDonald | |||
| Sean R Downing | |||
| Kyung Park | |||
| Roman Yelensky | |||
| Mirna Jarosz | |||
| Maureen T Cronin | |||
| P2860 | cites work | COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer | Q24608391 |
| Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | Q24616117 | ||
| The genomic complexity of primary human prostate cancer | Q24617949 | ||
| Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. | Q27824849 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| The Sequence Alignment/Map format and SAMtools | Q27860966 | ||
| The cancer genome | Q29547643 | ||
| The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
| The mutational landscape of head and neck squamous cell carcinoma | Q29614654 | ||
| Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma | Q33992803 | ||
| Personalized oncology through integrative high-throughput sequencing: a pilot study | Q34237470 | ||
| Clinical Implications of the Cancer Genome | Q34488700 | ||
| Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance | Q37036297 | ||
| Targeted therapy for cancer using PARP inhibitors | Q37222838 | ||
| Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer | Q37564765 | ||
| Exploring the genomes of cancer cells: progress and promise | Q37857590 | ||
| New therapies for castration-resistant prostate cancer: efficacy and safety | Q37877007 | ||
| Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets | Q39385550 | ||
| Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies | Q41923524 | ||
| Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. | Q42800727 | ||
| Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases | Q70169490 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| heterogeneity | Q928498 | ||
| P304 | page(s) | 920-926 | |
| P577 | publication date | 2012-09-05 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity | |
| P478 | volume | 63 |
| Q47953839 | A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer |
| Q38850529 | A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling |
| Q41369694 | A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents |
| Q89389032 | A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer |
| Q35754996 | A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. |
| Q38647048 | A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer |
| Q92015319 | A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer |
| Q58542898 | ATM deficiency promotes progression of CRPC by enhancing Warburg effect |
| Q53176477 | Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. |
| Q26795625 | Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer |
| Q92940559 | Advancing Risk Assessment of Intermediate Risk Prostate Cancer Patients |
| Q50174651 | Ambra1 induces autophagy and desensitizes human prostate cancer cells to cisplatin. |
| Q92713865 | An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients |
| Q48239804 | An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. |
| Q35142718 | An update on PARP inhibitors for the treatment of cancer |
| Q38833458 | Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. |
| Q48254505 | Anchored multiplex PCR for targeted next-generation sequencing |
| Q55251761 | Androgen action in prostate function and disease. |
| Q26866135 | Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases |
| Q36298863 | Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer |
| Q42188589 | Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer |
| Q33775723 | Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer |
| Q38977288 | Androgen receptor variation affects prostate cancer progression and drug resistance |
| Q37709535 | Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles |
| Q63884154 | BRCA2 and Other DDR Genes in Prostate Cancer |
| Q38699280 | BRCAness revisited |
| Q104795182 | BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C |
| Q38966736 | Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. |
| Q36891144 | Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors |
| Q42704874 | Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer |
| Q38697114 | Biomarkers in localized prostate cancer |
| Q49818426 | Cellular plasticity and the neuroendocrine phenotype in prostate cancer |
| Q38815964 | Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. |
| Q50075397 | Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. |
| Q49818398 | Clinical implications of PTEN loss in prostate cancer |
| Q54313342 | Clinical next-generation sequencing in patients with non-small cell lung cancer. |
| Q34871953 | Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms |
| Q38616693 | Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer |
| Q64109897 | Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer |
| Q38808811 | Clinical variability and molecular heterogeneity in prostate cancer |
| Q97419232 | Comparative analysis of somatic variant calling on matched FF and FFPE WGS samples |
| Q40903462 | Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer |
| Q38759487 | Controlled Release of Nor-β-lapachone by PLGA Microparticles: A Strategy for Improving Cytotoxicity against Prostate Cancer Cells. |
| Q38947366 | Copper signaling axis as a target for prostate cancer therapeutics |
| Q39164084 | Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer |
| Q49712140 | DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7. |
| Q52659702 | DNA Damage Response in Prostate Cancer. |
| Q38774228 | DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer |
| Q26829155 | DNA damage response and prostate cancer: defects, regulation and therapeutic implications |
| Q27853235 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer |
| Q41717391 | Detection of clinically relevant copy number alterations in oral cancer progression using multiplexed droplet digital PCR. |
| Q47163678 | Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing |
| Q35555483 | Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors |
| Q36606672 | Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression |
| Q46068832 | Differential impact of RB status on E2F1 reprogramming in human cancer |
| Q38768101 | Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer |
| Q38862172 | Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass. |
| Q38839110 | Drug discovery in advanced prostate cancer: translating biology into therapy |
| Q89454417 | EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers |
| Q42688396 | ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci |
| Q26777310 | Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer |
| Q39227406 | Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression |
| Q34560270 | Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel |
| Q26745956 | Evaluation of the methods to identify patients who may benefit from PARP inhibitor use |
| Q37690220 | Evaluation of ultra-deep targeted sequencing for personalized breast cancer care |
| Q27010542 | Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer |
| Q37139070 | Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer |
| Q53741649 | Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. |
| Q37300967 | Feasibility of RNA and DNA extraction from fresh pipelle and archival endometrial tissues for use in gene expression and SNP arrays |
| Q64079078 | Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation |
| Q35518233 | Flexible, scalable, and efficient targeted resequencing on a benchtop sequencer for variant detection in clinical practice |
| Q38649740 | Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies |
| Q30573750 | Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. |
| Q53787362 | Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. |
| Q64065002 | Genomic Characterization of Differentiated Thyroid Carcinoma |
| Q62746983 | Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer |
| Q38142173 | Genomic Rearrangements of PTEN in Prostate Cancer |
| Q39071381 | Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. |
| Q37067529 | Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification |
| Q34722101 | Genomic rearrangements in prostate cancer |
| Q33823048 | Genotyping the High Altitude Mestizo Ecuadorian Population Affected with Prostate Cancer |
| Q57694286 | High burden of copy number alterations andc-MYCamplification in prostate cancer fromBRCA2germline mutation carriers |
| Q91838148 | High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel |
| Q38220416 | High-risk prostate cancer: a disease of genomic instability |
| Q91611008 | Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis |
| Q39113039 | Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis |
| Q89866396 | Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer |
| Q50099775 | Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform |
| Q45968823 | Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. |
| Q41136692 | Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer |
| Q38973231 | Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate |
| Q26795589 | Insights into Chemoresistance of Prostate Cancer |
| Q27853170 | Integrative clinical genomics of advanced prostate cancer |
| Q49242804 | Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. |
| Q27022288 | Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression |
| Q47846573 | Invasive breast carcinomas with ATM gene variants of uncertain significance share distinct histopathologic features |
| Q36004694 | Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer |
| Q57111633 | Lineage plasticity-mediated therapy resistance in prostate cancer |
| Q38123680 | Luminal breast cancer: from biology to treatment |
| Q50133991 | Molecular Biomarkers in the Clinical Management of Prostate Cancer |
| Q52608488 | Molecular and cellular mechanisms of castration resistant prostate cancer. |
| Q50440575 | Molecular characterization of oral squamous cell carcinoma using targeted next-generation sequencing. |
| Q42184292 | Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues |
| Q39172297 | Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets |
| Q26739708 | Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer |
| Q38150909 | Molecular pathological analysis of sarcomas using paraffin-embedded tissue: current limitations and future possibilities |
| Q38151036 | Molecular pathology and prostate cancer therapeutics: from biology to bedside |
| Q33862462 | Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy |
| Q34365632 | Molecular pathways and targets in prostate cancer |
| Q100526071 | Molecular tracing of prostate cancer lethality |
| Q64923497 | Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis. |
| Q53638595 | Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing. |
| Q38752466 | Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. |
| Q42777878 | Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer |
| Q33870601 | Mutations in BRCA2 and taxane resistance in prostate cancer |
| Q34007943 | New strategies in prostate cancer: translating genomics into the clinic |
| Q34669370 | Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance |
| Q38384489 | Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment |
| Q44582971 | Novel preclinical models and biomarkers for prostate cancer |
| Q36888450 | Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer |
| Q92257452 | PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development |
| Q47406034 | PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis |
| Q64821204 | Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy |
| Q97643299 | Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion |
| Q37218177 | Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b |
| Q26748603 | Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine |
| Q37114034 | Precision medicine for advanced prostate cancer |
| Q38263711 | Precision medicine for prostate cancer |
| Q50105699 | Precision oncology in the age of integrative genomics. |
| Q47893779 | Preclinical and Coclinical Studies in Prostate Cancer |
| Q92198287 | Predicting clinical outcome of therapy-resistant prostate cancer |
| Q36119886 | Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction |
| Q57115094 | Profiles of Radioresistance Mechanisms in Prostate Cancer |
| Q104611756 | Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary |
| Q57121731 | Prostate cancer |
| Q55172706 | Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways. |
| Q30656758 | Prostate cancer invasion and metastasis: insights from mining genomic data |
| Q91669835 | Prostate tumor neuroendocrine differentiation via EMT: The road less traveled |
| Q61811956 | Prostate-specific loss of UXT promotes cancer progression |
| Q52629153 | Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. |
| Q38180318 | Rapid learning for precision oncology |
| Q39342369 | Rationale for the development of alternative forms of androgen deprivation therapy |
| Q39044979 | Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma |
| Q54111821 | Recent Advances in Prostate Cancer Treatment and Drug Discovery. |
| Q38366212 | Reprint of: The prostate cancer genome: Perspectives and potential. |
| Q35881001 | Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples. |
| Q90292648 | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer |
| Q38240726 | Sequencing approaches in cancer treatment |
| Q37305642 | Single-cell intracellular nano-pH probes. |
| Q36087015 | Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA |
| Q38703676 | Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer. |
| Q36483762 | Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling |
| Q38387844 | Synergistic action of image-guided radiotherapy and androgen deprivation therapy |
| Q52645860 | Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. |
| Q102211141 | TP53 alterations of hormone-naïve prostate cancer in the Chinese population |
| Q100526333 | Targetable gene fusions and aberrations in genitourinary oncology |
| Q38384791 | Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics |
| Q91669842 | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer |
| Q27022821 | Targeting the adaptive molecular landscape of castration-resistant prostate cancer |
| Q57106057 | Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer |
| Q57113379 | The Genomics of Prostate Cancer: A Historic Perspective |
| Q48317607 | The Genomics of Prostate Cancer: emerging understanding with technologic advances |
| Q38982680 | The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment |
| Q61805988 | The Secret Life of Translation Initiation in Prostate Cancer |
| Q41839243 | The context of prostate cancer genomics in personalized medicine |
| Q52363678 | The crucial role of multiomic approach in cancer research and clinically relevant outcomes. |
| Q38090427 | The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing |
| Q39190147 | The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. |
| Q38374417 | The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer |
| Q38109474 | The genomic landscape of prostate cancer |
| Q26992049 | The many faces of neuroendocrine differentiation in prostate cancer progression |
| Q26851631 | The mutational landscape of prostate cancer |
| Q33408750 | The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial |
| Q38163225 | The prostate cancer genome: perspectives and potential. |
| Q37385372 | The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe |
| Q42139770 | Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity |
| Q37270512 | Translational and clinical implications of the genetic landscape of prostate cancer |
| Q42220108 | Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. |
| Q34372080 | Tumour heterogeneity in the clinic |
| Q38842168 | Tumour heterogeneity: principles and practical consequences |
| Q41906700 | Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens |
| Q47818549 | WNT signalling in prostate cancer. |
| Q27853005 | Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine |
| Q92410960 | Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance |
| Q87054413 | [Personalized urooncology based on molecular uropathology: what is the future?] |
Search more.